BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public
25.5.2018 09:00:00 EEST | Business Wire | Press release
Since Wednesday, May 16, investors finally have a chance to claim their share of a unique success story, the international market roll-out of Aimedis, by purchasing AIM tokens: AIM tokens are now available with a 20% presale bonus PLUS a 5% early bird-premium only at the Czech investment house BRIC INVEST https://www.bric-holding.com/home_en.html!
Aimedis aims to shape the future of healthcare by providing an advanced and fully operational platform, secured by blockchain and supported by AI, that enables patients to take control, secure the exchange of their medical data, access the best healthcare providers, get advice, prescriptions, personal health upgrades and to become part of the health revolution. And we are not talking about the future: The revolutionary Aimedis platform is already deployed as a live working system and is already in use in major hospital groups in Germany!
By issuing 300 million AIM tokens at a nominal value of 0,12 USD each, the Aimedis consortium will raise ca. 36 million US dollars to finance the global roll-out of the successful platform, starting in China and other countries of the far east. Also, the AIM token will help to jump-start the ecosystem within the platform: AIM will be the currency inside the system, enabling participants to buy and sell drugs, services such as consultations, pay for prescriptions, and last, but not least, support other patients who provide valuable health related information i.e. by setting up special interest groups, sharing experiences or rating doctors, services and medicaments.
The leading benchmark portal for ICOs, www.icobench.com, rates the Initial Market Offering with 4.6 out of 5 possible points, making the AIM-ICO the currently best-rated eHealth ICO on the portal. Above all two arguments lead to this TOP-rating: First, that the system is already live and is used by larger hospital corporations in Germany, and secondly, that behind the Aimedis ICO stands an impressive phalanx of health „celebreties“, that serving as members of the Advisory Board, will certainly contribute to the success of the platform.
Miro Soukup, chairman of the Czech investment firm BRIC INVEST, concludes: “With our offering of AIM tokens with a presale bonus of 20% and our early bird-premium of 5% on top, investors have a unique chance to purchase their share of Aimedis, thus participating in the emergence of the new eHealth markets that will sooner than later change the way how patients interact with all other members and players in the health industry of the future.”
More information on the AIM and Aimedis: https://www.bric-holding.com/aimedis-ico-EN.html
Buy AIM tokens now: https://www.bric-holding.com/contact_us_en.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005523/en/
Contact information
BRIC HOLDING SE
Miroslav Soukup
Tel.: +420774773443
E-Mail:
invest@bric-holding.com
Web:
https://www.bric-holding.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports Full Year and Fourth Quarter 2025 Results12.2.2026 08:01:00 EET | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/ Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 “Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer environment. We exit 2025 with improved momentum and enter 2026 well positioned to engage consumers with our megabrands and an unparalleled lineup of mega platforms. Thank you to our colleagues for their ongoing commitment, hard work and passion for our business.” – Michel Doukeris, CEO, AB InBev Revenue 4Q +2.5% | FY +2.0% Revenue increased by 2.5% in 4Q25 with revenue per hl growth of 4.0% and by 2.0% in FY25 with rev
Bardasz Forms Strategic Digital Alliance with GEOLOG to Accelerate Global RTOC Delivery and Digital Well Construction Solutions12.2.2026 08:00:00 EET | Press release
Bardasz Group LLC (“Bardasz”), a provider of real-time, decision-ready intelligence for well construction—including drilling, completions, and well interventions—today announced a strategic digital alliance with GEOLOG International B.V. (“GEOLOG”), a global formation evaluation, drilling, and geochemistry services provider supporting subsurface projects in more than 40 countries. The alliance is designed to accelerate Bardasz’s global growth and enhance customer delivery by leveraging GEOLOG’s in-country resources, technical expertise, and operational scale. Bardasz helps operators transform fragmented well construction data into actionable intelligence across assets—enabling faster integration, increased reliability of real-time data workflows, and improved rig-time efficiency with reduced non-productive time (NPT). Bardasz’s high-frequency real-time well construction platform is built on best-in-class WITSML and ETP standards and is engineered for scaled, enterprise-grade environmen
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties12.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211375008/en/ Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.2-6 With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerati
Lenovo Group: Third Quarter Financial Results 2025/2612.2.2026 06:13:00 EET | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported results for the third quarter of fiscal year 2025/26, a quarter that delivered record revenues, accelerated profitability, and continued AI revenue expansion. During the quarter, overall group revenue reached an all-time fiscal quarter high of US$22.2 billion, up 18% year-on-year, with revenue from all business groups growing double-digit year-on-year. Excluding non-operating non-cash items and one-time gains and charges in Q3 FY24/25 and Q3 FY25/26, adjusted net income (profit attributable to equity holders – non-HKFRS)[1] increased by 36% year-on-year to US$589 million, with adjusted net income margin[1] expanding to 2.7%. The results demonstrate the Group’s ability to deliver on its promise of double-digit growth and sustained profitability, while proving its ability to manage through cycles by leveraging innovation to drive growth and operational excellence to navigate volatil
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 23:36:00 EET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improved our financial flexibility, allowing us to direct resources to our highest-value businesses.” “Looking ahead to 2026, we are continuing to serve our customers with leading innovation to grow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom